# Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression

> **NCT05129189** · PHASE2 · UNKNOWN · sponsor: **Shanghai Public Health Clinical Center** · enrollment: 15 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** ASC22 group

## Key facts

- **NCT ID:** NCT05129189
- **Lead sponsor:** Shanghai Public Health Clinical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-29
- **Primary completion:** 2023-07-30
- **Final completion:** 2023-07-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2022-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05129189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05129189, "Functional Cure Study of Anti-PD-L1 Antibody ASC22 in Combination With Chidamide in HIV-infected Patients With Antiviral Suppression". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05129189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*